Nona Biosciences, a leading biotechnology company, has unveiled its innovative AI-assisted drug discovery engine, Hu-mAtrIxTM, which integrates seamlessly with its proprietary Harbour Mice® technology platform. This cutting-edge technology aims to accelerate antibody discovery in key therapeutic areas such as neurodegenerative and metabolic diseases. The Hu-mAtrIxTM platform streamlines the antibody discovery process, shortening timelines, increasing efficiency, and improving success rates by leveraging AI and automation technologies.
The platform offers integrated solutions for identifying high-efficiency antibodies with desired target specificity and binding affinity. It also predicts key antibody properties like stability and immunogenicity, reducing development risks. Nona Biosciences is also developing a new AI model to enhance its HCAb PlusTM core technology platform, allowing for the identification of rare, highly specific antibodies with greater precision.
Dr. Jingsong Wang, Chairman of Nona Biosciences, highlighted the benefits of combining the Harbour Mice® platform with AI, addressing key challenges in drug discovery and providing partners with more targeted therapeutic options. Nona Biosciences is committed to innovation and offers a range of antibody discovery services, leveraging the advantages of its platforms and experienced team to drive the invention of next-generation drugs.
For more information about Nona Biosciences and its advanced AI technology in antibody discovery, visit their website at www.nonabio.com.
————————————————————————
Note: The image is for illustrative purposes only and is not the original image associated with the presented article. Due to copyright reasons, we are unable to use the original images. However, you can still enjoy the accurate and up-to-date content and information provided.
————————————————————————
